1. Platinum-based chemotherapy increased TXNIP expression, and overexpression of TXNIP enhanced the effectiveness of this therapy.
Platinum-based chemotherapy increased TXNIP expression, and overexpression of TXNIP enhanced the effectiveness of this therapy. A, Cells were treated with cisplatin for 72 hours at the concentrations indicated. qRT-PCR and immunoblots of TXNIP expression were normalized with β-actin. B, Flo-1 overexpressing TXNIP were treated with 4 μg/mL of cisplatin, and Esc2 overexpressing TXNIP were treated with 1.0 μg/mL of cisplatin for 24 hours. qRT-PCR and immunoblots of TXNIP expression were normalized with β-actin. C, Esc2 cells with lentiviral shRNA knockdown of TXNIP were treated with 1.5 μg/mL of cisplatin for 24 hours. qRT-PCR and immunoblots of TXNIP expression were normalized with β-actin. D, Cell lines were treated with the same time and concentrations as in B, after which γH2AX immunofluorescent staining was performed. In Flo-1, puncts were counted in 50 cells from each group. Esc2 had very high γH2AX uptake, and so levels were categorized based on percent staining intensity. E–F, Annexin V Apoptosis Assay was performed after cisplatin treatment as described in B.
Paul L. Feingold et al. Mol Cancer Ther 2018;17:
©2018 by American Association for Cancer Research